Bleeding diathesis in multiple myeloma

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 5, 2001, Pages 657-660

  Saif, M W ^a   Allegra, C J ^b   Greenberg, B ^c  

^a University of Alabama at Birmingham   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Chester County Department of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN MONOMER; GROWTH FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; MELPHALAN; PARAPROTEIN; PROTAMINE;

ADULT; ARTICLE; BLEEDING TENDENCY; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOSIS;

BLOOD COAGULATION FACTORS; FEMALE; HEMORRHAGIC DISORDERS; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBIN TIME;

EID: 0034774853     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581601753193869     Document Type: Article

References (18)

1. Hemorrhagic diathesis in multiple myeloma
2. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder
3. Platelet function and survival in multiple myeloma
4. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin
5. Increased thrombin time in a patient with multiple myeloma
6. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder
7. Heparin-like anticoagulant associated with plasma cell myeloma
8. Circulating heparan sulfate proteoglycan from a patient with a plasma cell disorder
9. Hemostasis abnormalities associated with dysproteinemias
10. Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency
11. Hemostatic defects associated with dysproteinemias
12. Platelet functions in dysproteinaemia
13. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder
14. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor
15. Autoantibody inhibits binding of von Willebrand factor to glycoproteinIb and collagen in multiple myeloma: Recognition sites present on the A1 loop and A3 domains of von Willebrand factor
16. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis
17. Tumor immunoglobulin with antibody activity against blood coagulation factors
18. Hemostatic abnormalities in multiple myeloma and related disorders